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Summary
Background The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest eﬃ  cacy of the vaccine 
against Plasmodium falciparum malaria, but was not powered to assess mortality endpoints. Impact projections and 
cost-eﬀ ectiveness estimates for longer timeframes than the trial follow-up and across a range of settings are needed 
to inform policy recommendations. We aimed to assess the public health impact and cost-eﬀ ectiveness of routine use 
of the RTS,S/AS01 vaccine in African settings.
Methods We compared four malaria transmission models and their predictions to assess vaccine cost-eﬀ ectiveness 
and impact. We used trial data for follow-up of 32 months or longer to parameterise vaccine protection in the group 
aged 5–17 months. Estimates of cases, deaths, and disability-adjusted life-years (DALYs) averted were calculated over 
a 15 year time horizon for a range of levels of Plasmodium falciparum parasite prevalence in 2–10 year olds 
(PfPR2–10; range 3–65%). We considered two vaccine schedules: three doses at ages 6, 7·5, and 9 months (three-dose 
schedule, 90% coverage) and including a fourth dose at age 27 months (four-dose schedule, 72% coverage). We 
estimated cost-eﬀ ectiveness in the presence of existing malaria interventions for vaccine prices of US$2–10 per dose.
Findings In regions with a PfPR2–10 of 10–65%, RTS,S/AS01 is predicted to avert a median of 93 940 (range 20 490–126 540) 
clinical cases and 394 (127–708) deaths for the three-dose schedule, or 116 480 (31 450–160 410) clinical cases and 
484 (189–859) deaths for the four-dose schedule, per 100 000 fully vaccinated children. A positive impact is also 
predicted at a PfPR2–10 of 5–10%, but there is little impact at a prevalence of lower than 3%. At $5 per dose and a PfPR2–10 
of 10–65%, we estimated a median incremental cost-eﬀ ectiveness ratio compared with current interventions of $30 
(range 18–211) per clinical case averted and $80 (44–279) per DALY averted for the three-dose schedule, and of $25 
(16–222) and $87 (48–244), respectively, for the four-dose schedule. Higher ICERs were estimated at low PfPR2–10 levels.
Interpretation We predict a signiﬁ cant public health impact and high cost-eﬀ ectiveness of the RTS,S/AS01 vaccine 
across a wide range of settings. Decisions about implementation will need to consider levels of malaria burden, the 
cost-eﬀ ectiveness and coverage of other malaria interventions, health priorities, ﬁ nancing, and the capacity of the 
health system to deliver the vaccine.
Funding PATH Malaria Vaccine Initiative; Bill & Melinda Gates Foundation; Global Good Fund; Medical Research 
Council; UK Department for International Development; GAVI, the Vaccine Alliance; WHO.
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Introduction
In the past 15 years, renewed investment in malaria 
control has led to substantial reductions in malaria 
worldwide.1,2 Despite this investment, malaria remains a 
leading cause of morbidity and mortality.1 Investigators 
have completed phase 3 testing of the RTS,S/AS01 
Plasmodium falciparum vaccine candidate in two age 
groups at 11 centres in sub-Saharan Africa.3 Eﬃ  cacy 
against clinical malaria was 20·3% (95% CI 13·6–26·5) 
in infants aged 6–12 weeks and 35·2% (30·5–39·5) in 
children aged 5–17 months during 32 months of 
follow-up. Vaccine eﬃ  cacy against clinical malaria 
declined over time, from 45·1% (95% CI 41·4–48·7%) 
during months 0–20 to 16·1% (8·5–23·0%) during 
months 21–32 in children, and from 27·0% (21·1–32·5) 
to 7·6% (–1·4 to 15·9%), respectively, in infants. In the 
group given a fourth dose of vaccine 18 months after the 
initial course, eﬃ  cacy against clinical malaria was 43·9% 
(95% CI 39·7–47·8) in children and 27·8% (21·7–33·4) 
in infants over 32 months.
Levels of malaria incidence and seasonality proﬁ les 
varied across the 11 trial sites, and malaria incidence 
ranged from 0·03 to 4·27 clinical episodes per infant 
per year in the control group, which is broadly 
representative of settings in Africa.4 However, these 
estimates were obtained in cohorts with a high coverage 
of long-lasting insecticide-treated nets (75–80% in both 
intervention and control groups) and in the presence of 
high levels of good-quality access to care. Thus, mortality 
was lower in children in the control group than in the 
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general population outside the trial and elsewhere in 
Africa, as shown for one of the study sites.5 Of note was 
the very small number of malaria deaths (19 [<1%] of 
8922 children died over a median of 48·1 months 
[IQR 39–50] of follow-up3), probably because of the high 
level of care for trial participants. Estimates of the public 
health impact and cost-eﬀ ectiveness of the vaccine in 
diﬀ erent African settings with more typical access to care 
and current intervention coverage are needed to inform 
global and national decisions about vaccine introduction. 
In particular, estimations should be made of the impact 
on both morbidity and mortality in the absence of high 
levels of treatment to ensure that appropriate comparisons 
can be made between the cost-eﬀ ectiveness of this vaccine 
and other childhood vaccines.
Mathematical models of malaria dynamics can be 
useful for estimation of the potential public health 
impacts of malaria vaccination beyond the eﬃ  cacy 
estimates obtained from the individually randomised 
clinical trial. An important feature of these models is that 
they have been extensively parameterised to routine data 
from endemic settings. Additionally, the models capture 
potential age-shifting of cases to older ages, as shown for 
severe malaria in the phase 3 trial, but that would not be 
expected to be shown in 4 years of follow-up. Furthermore, 
via use of data relating clinical disease to death, models 
can be used to estimate eﬀ ects on mortality based on 
realistic assumptions about treatment in non-trial 
settings. In line with WHO recommendations about 
use of cost-eﬀ ectiveness information within the 
decision-making process for introduction of new 
vaccines,6,7 and for impact estimates from GAVI, the 
Vaccine Alliance,8 we systematically compared four 
malaria transmission models to assess the public health 
impact and cost-eﬀ ectiveness of routine use of the 
RTS,S/AS01 vaccine in African settings.
Methods
Models and harmonisation assumptions
Modelling groups were contacted by WHO to participate 
in this study. Four groups agreed to contribute: the 
Institute for Disease Modeling (EMOD-DTK),9 GSK 
Vaccines (GSK),10 Imperial College London (Imperial),11 
and the Swiss Tropical and Public Health Institute 
(OpenMalaria).12 The four models encompass a range of 
structures and levels of complexity, with all simulating 
malaria transmission and vaccine impact for deﬁ ned 
geographic areas, taking into account local exposure 
Research in context
Evidence before this study
The phase 3 trial of the RTS,S/AS01 vaccine provides estimates 
of cases averted at the 11 trial sites. However, these estimates 
need to be translated into full population impact to calculate 
the cost-eﬀ ectiveness of the vaccine compared with other 
malaria interventions. Mathematical models have previously 
estimated the public health impact and cost-eﬀ ectiveness of 
malaria vaccines in diﬀ erent settings. We searched PubMed, the 
Cochrane Library, and other relevant data sources between 
April 1, 2015, and June 8, 2015, for studies of predictions and 
the cost-eﬀ ectiveness of RTS,S malaria vaccine. The literature 
covered the period 2006, to June, 2015. We searched PubMed 
with the MeSH terms “RTS,S” [All Fields] AND “malaria” [All 
Fields] AND “model” [All Fields] OR “simulation” [All Fields] OR 
“prediction” [All Fields]. For the Cochrane Library and other data 
sources, we used the search terms “RTS,S”, AND “predictions”. 
The 29 manuscripts identiﬁ ed included 14 reports that referred 
to RTS,S or pre-erythrocytic vaccines and model analysis or 
predictions. Ten of these reports did not use trial data to 
parameterise models or were limited to data from phase 2 trials 
of RTS,S with a diﬀ erent adjuvant (AS02) or for vaccination in a 
diﬀ erent age group, whereas the other four reports made 
predictions of RTS,S or similar malaria vaccine candidates, but 
with vaccines parameterised from either intermediate phase 3 
results or phase 2 trial data for RTS,S/AS01. Of these 
14 publications, 12 were based on models included in the 
present study. A search for “malaria model” [All Fields] and 
“comparison” [All Fields] identiﬁ ed no publications that 
compared malaria transmission models.
Added value of this study
This is the ﬁ rst study to estimate the public health impact of 
the vaccine and its cost-eﬀ ectiveness in populations beyond 
the trial with multiple mathematical models to address 
structural model uncertainty. This is also the ﬁ rst modelling 
study to use ﬁ nal site-speciﬁ c results of the RTS,S phase 3 
clinical trial and to systematically compare the malaria 
transmission models. Predictions are made for the full range 
of Plasmodium falciparum parasite prevalence settings 
in Africa.
Implications of all available evidence
The RTS,S malaria vaccine candidate provided modest 
protection against clinical malaria in children across diﬀ erent 
disease burden settings in the phase 3 clinical trial. A WHO 
recommendation for vaccine use in endemic Africa will 
additionally need to consider the public health impact and 
cost-eﬀ ectiveness informed by our model predictions. This 
study reports on the major collaborative exercise coordinated 
by WHO undertaken for this purpose. Our results quantify the 
potential number of cases and deaths that could be averted by 
the RTS,S/AS01 vaccine when implemented in moderate to 
high transmission with full vaccine coverage and in the 
presence of existing malaria control interventions. Decisions 
about implementation will need to consider levels of malaria 
burden, the cost-eﬀ ectiveness and coverage of other malaria 
interventions, health priorities, ﬁ nancing, and the capacity of 
the health system to deliver the vaccine.
See Online for appendix
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and population demographics. Two models (Imperial 
and OpenMalaria) capture any herd eﬀ ect of vaccination, 
whereas the other two models (EMOD-DTK and 
GSK) are implemented as a ﬁ xed-exposure cohort. 
Appendix pp 5–20 provide a full comparison of 
the models.
We used trial data3 for follow-up of 32 months or longer 
to parameterise vaccine eﬃ  cacy against infection for the 
group aged 5–17 months. EMOD-DTK, GSK, and 
OpenMalaria13 used site-speciﬁ c incidence or eﬃ  cacy data 
aggregated into 3 month periods, and Imperial14 used 
individual-level data. We assumed no partial protection 
from the initial two doses, consistent with primary 
reporting from the trial.3 With use of these estimates 
derived from the trial data, we then made projections for 
wider transmission settings representative of normal 
access to care. Demographics, Plasmodium falciparum 
parasite prevalence in 2–10 year olds (PfPR2–10; a standard 
metric used to describe the intensity of malaria 
transmission2), seasonality, and case management were 
aligned across the models (table 1). We assumed that 
access to artemisinin-based combination therapy was 
45%, at the top of the range reported in 2013,1 but 
signiﬁ cantly lower than in the trial.
We predicted the public health impact and cost-
eﬀ ectiveness of the vaccine for a range of PfPR2–10 levels 
(3–65%), assuming vaccine implementation was in 
addition to existing levels of malaria control interventions 
and treatment under the assumptions in table 1. We 
considered two immunisation schedules: three doses at 
age 6, 7·5, and 9 months (6–9 months with a three-dose 
schedule), and with an additional fourth dose at 
27 months of age (6–9 months with a four-dose schedule). 
We chose these schedules because two visits (months 6 
and 9) align with routine health-care visits (vitamin A 
supplement at 6 months and measles complex vaccine at 
9 months). We focus on the cohort aged 5–17 months 
because eﬃ  cacy was higher in this group than in the 
group aged 6–12 weeks.3 For both schedules, we deﬁ ned 
a fully vaccinated child as a child who had received at 
least three doses.
We assumed 90% vaccine coverage (similar to 
diphtheria-tetanus-pertussis [DTP3] in Africa16) for 
6–9 month implementation, with 80% of these individuals 
receiving the fourth dose (72% coverage) based on a 
drop-oﬀ  in coverage from DTP3 to measles vaccination at 
9 months (table 1).16 We summarise outputs as 
clinical cases, severe cases, deaths, and undiscounted 
disability-adjusted life-years (DALYs; driven mainly by 
mortality) averted per 100 000 fully vaccinated children. 
Outputs are cumulative over a 15 year time horizon, 
chosen to be comparable to the timeframe of the new 
Global Technical Strategy for malaria17 and over a length 
of time that is long enough to capture any potential 
detrimental eﬀ ect of shifting of cases to older ages. We 
report health outcomes for the entire population and for 
children younger than 5 years.
Harmonised comparison
Demographics Constant population size and demography based on the life table for Butajira, Ethiopia, 
with an average life expectancy at birth of 46·6 years.15
Transmission 
intensity
Parasite prevalence in 2–10 year olds between 3% and 65%, representing current 
transmission levels in Africa.2
Seasonality Perennial transmission (no seasonality).
Case 
management
Eﬀ ective coverage (ie, treatment with parasitological cure) for clinical malaria is 45%. 
Access to care for severe malaria varied by model.
Other 
interventions
Predictions assume that current interventions in place at the start of vaccination remain at 
static levels.
Vaccine 
eﬃ  cacy
Model estimates of RTS,S eﬃ  cacy against infection proﬁ les based on ﬁ tting to phase 3 trial 
data (appendix pp 22–30).
Vaccine 
schedule
Three doses of vaccine given at 6, 7·5, and 9 months (6–9 month implementation) with a 
fourth dose at month 27 (6–9 month with fourth dose). The ﬁ rst two doses of the primary 
series are assumed to have 0% eﬃ  cacy.
Vaccine 
coverage
90% coverage assumed for the three-dose schedule; we assumed a 20% drop-oﬀ  in 
coverage for the fourth dose (72% coverage).
Cost of RTS,S 
vaccination
Vaccine and immunisation supplies including freight and wastage. The same costs were 
applied to all settings. These costs were estimated at US$6·52 per dose at vaccine price of 
$5, $2·69 per dose at vaccine price of $2, and $12·91 at vaccine price of $10 
(appendix pp 33–34).
Cost of malaria 
case 
management
Costs are estimated by severity of illness and cover ﬁ rst-line antimalarial drugs, diagnostics, 
and related supplies including freight and wastage. We assumed full compliance and 
adherence with the age dosage. The same costs were applied to all settings, ranging from 
$1·07 to $2·27 per uncomplicated case, and from $21·78 to $55·58 per severe case 
(appendix pp 33–34).
Table 1: Assumed demographics, implementation coverage, and vaccine eﬃ  cacy proﬁ les
Figure 1: Observed and model-predicted vaccine eﬃ  cacy against clinical and severe malaria from month 0 to 
study end (≥32 months) by study site in the 5–17 month age category
Vaccine eﬃ  cacy against all episodes of clinical malaria (primary case deﬁ nition) in the three-dose group (A) and 
the four-dose group (B), and against severe malaria (primary case deﬁ nition) in the three-dose group (C) and the 
four-dose group (D). Error bars show 95% CIs estimated from the trial data. *Intention-to-treat analysis.
Kiliﬁ
Korogwe
Manhica
Lambarene
Bagamoyo
Lilongwe
Agogo
Kombewa
Kintampo
Nanoro
Siaya
Eﬃcacy against clinical malaria (%)
0–50–100 10050
Eﬃcacy against clinical malaria (%)
0–50–100 10050
A Three-dose group B Four-dose group
Kiliﬁ
Korogwe
Manhica
Lambarene
Bagamoyo
Lilongwe
Agogo
Kombewa
Kintampo
Nanoro
Siaya
Eﬃcacy against severe malaria (%)
0–50–100 10050
Eﬃcacy against severe malaria (%)
0–50–100 10050
C Three-dose group D Four-dose group
Trial data*
GSK
EMOD–DTK
Imperial
OpenMalaria
Articles
370 www.thelancet.com   Vol 387   January 23, 2016
We did this study in accordance with Good Clinical 
Practice guidelines and the Declaration of Helsinki. The 
trial protocol was approved by the ethical review board at 
each study centre and partner institution and by the 
national regulatory authority in each country.18 Because 
this work involves data simulations and analysis, 
informed consent was not required.
Statistical analysis
We estimated the incremental cost per clinical case or 
DALY averted compared with no vaccination with 
standard levels of access to treatment and other malaria 
interventions (with costs discounted at 3%). We 
evaluated incremental cost for assumed vaccine 
purchase prices of US$2, $5 and $10, corresponding to a 
cost per dose of $2·69, $6·52, and $12·91, respectively 
(table 1, appendix pp 33–34). We calculated costs from 
the perspective of the health-care provider, which include 
the cost of consumables (vaccines and immunisation 
supplies) for RTS,S introduction, diagnostics, and 
antimalarial drugs, and related commodities for malaria 
case management (table 1). We undertook a univariate 
sensitivity analysis of vaccine properties, health systems, 
and economic parameters for the OpenMalaria model 
(appendix pp 48–50).
We present outputs from each model as medians and 
95% prediction intervals. We present summary outputs 
across the four models as the median of all models 
plus ranges across the medians of the individual 
models.
Role of the funding sources
The PATH Malaria Vaccine Initiative contributed to 
study design and data interpretation. The Health 
Economics Group of GSK Vaccines was involved in data 
analysis, data interpretation, and writing of the report (as 
one model group in the comparison), but had no role in 
the opinions and results presented by the other groups. 
Figure 2: Model predictions of clinical cases and deaths averted per 100 000 children fully vaccinated with a three-dose or four-dose immunisation schedule 
for a range of baseline PfPR2–10 levels
Results for the three-dose (A, C) and four-dose (B, D) schedules are cumulative following 15 years of routine use of RTS,S. Bars show median estimates and error bars 
show 95% credible intervals. Negative cases averted at low transmission are due to stochastic variation between model runs at low prevalence, rather than to any 
modelled biological mechanism. PfPR2–10=parasite prevalence in 2–10 year olds.
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All other funders of the study had no role in study design, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to the data and were jointly 
responsible for the decision to submit the manuscript.
Results
Figure 1 shows the trial and model-estimated cumulative 
vaccine eﬃ  cacy by trial site at study end (≥32 months). 
Model-estimated eﬃ  cacy generally falls within the 
conﬁ dence intervals of the trial data for both clinical 
malaria and severe disease (ﬁ gure 1). The estimated 
underlying protection against infection was similar 
across models during the ﬁ rst 18 months, but diverged as 
the projections extended beyond the trial period 
(appendix pp 21–31).
With the four mathematical models and our 
assumptions about implementation of the vaccine 
beyond the trial sites, we estimated that the absolute 
vaccine impact would increase with increasing levels of 
malaria transmission, averting from 15–32% of all 
clinical cases at a PfPR2–10 of 10%, to 5–22% of clinical 
cases at a PfPR2–10 of 65% (ﬁ gure 2, table 2). Similarly, we 
estimated that 8–35% of malaria deaths in children 
younger than 5 years would be averted at a PfPR2–10 of 
10%, and 5–24% would be averted at a PfPR2–10 of 65% 
(ﬁ gure 2, table 2). The predicted lower proportion of 
events averted in higher versus lower transmission areas 
is partly a result of age-shifting of disease in higher 
transmission areas (ﬁ gure 3, appendix pp 36–47). Across 
the models this ﬁ nding translates to a median of 116 480 
(range 31 450—160 410) cases of clinical malaria averted 
and 484 (189–859) deaths averted per 100 000 vaccinated 
children with the four-dose schedule for a PfPR2–10 of 
10–65% (ﬁ gure 2, table 2). Public health impact at a 
PfPR2–10 of less than 3% is expected to be small 
(ﬁ gure 2, appendix pp 36–47).
There was a lack of consensus between the models for 
the additional public health impact of the four-dose 
versus the three-dose schedule. Three models (GSK, 
EMOD-DTK, Imperial) predicted a substantial additional 
impact of the four-dose schedule (16–43% extra deaths 
averted and 21–55% extra clinical cases averted; table 2), 
whereas the fourth model (OpenMalaria) predicted a 
marginal impact. This variance is due to diﬀ erences in 
the estimated impact of the fourth dose against infection 
and the estimated waning of protection against infection 
between the models (appendix pp 21–31).
As expected with partially eﬀ ective malaria control 
interventions,19,20 we predicted a shift in cases to older 
ages due to reduced exposure and hence a delay in the 
development of naturally acquired immunity. Combined 
with the estimated waning of protection against infection 
of the vaccine, some of the initial impact of the vaccine 
on cases averted in very young children is therefore oﬀ set 
by predicted higher relative incidence at older ages 
(ﬁ gure 3). This eﬀ ect is predicted to be further delayed 
with the four-dose schedule (appendix pp 36–47). Similar 
eﬀ ects are predicted for severe disease, with the age-shift 
occurring earlier than for clinical cases (appendix 
pp 36–47). Despite these ﬁ ndings, the overall cumulative 
impact of the vaccine on clinical cases, severe disease, 
and mortality over 15 years is predicted to be positive 
with the four-dose vaccine schedule (ﬁ gure 3). Our 
analyses also assume that malaria exposure remains 
static for the length of follow-up. Thus, this age-shifting 
eﬀ ect could be mitigated if transmission declines over 
this time horizon (eg, as a result of continued scale-up of 
other interventions21).
The estimated incremental cost-eﬀ ectiveness ratios 
(ICERs) for clinical cases and DALYs averted with both 
vaccination schedules compared with no vaccination 
were lowest at intermediate levels of PfPR2–10, but were 
generally less than $100 per DALY averted for a PfPR2-10 of 
more than 10% for a vaccine price of $5 per dose (table 2, 
ﬁ gure 4). At a PfPR2–10 of less than 10% the vaccine is 
estimated to become substantially less cost-eﬀ ective due 
to fewer cases and deaths being averted for the same 
overall cost of a vaccine programme (ﬁ gure 4). 
Furthermore, consensus between the models is lower at 
a PfPR2–10 of less than 10% than at a PfPR2–10 of more than 
10% (ﬁ gure 4). The predicted ICER of a four-dose 
schedule varied between the models because of the 
diﬀ erent public health impact projections of the fourth 
dose. However, overall we estimated that the ICERs 
(compared with no vaccination) for the four-dose 
schedule were similar to those estimated for the 
three-dose schedule (table 2). This similarity is because 
Three-dose schedule Four-dose schedule
Proportion of clinical cases averted in children 
younger than 5 years
16·2% (7·3–24·1) 21·1% (7·9–30·6)
Proportion of deaths averted in children 
younger than 5 years
13·8% (5·3–21·4) 18·0% (6·0–29·1)
Clinical cases averted per 100 000 fully 
vaccinated children
93 940 (20 490–126 540) 116 480 (31 450–160 410)
Deaths averted per 100 000 fully vaccinated 
children
394 (127–708) 484 (189–859)
Incremental beneﬁ t*
Clinical cases ·· 22% (3 to 49)
Deaths ·· 31% ( –1 to 53)
ICER per clinical case averted (in US$)
$2 per dose $13 (7–88) $10 (6–93)
$5 per dose $30 (18–211) $25 (16–222)
$10 per dose $61 (31–415) $51 (28–437)
ICER per DALY averted (in US$)
$2 per dose $35 (16–112) $38 (18–97)
$5 per dose $80 (44–279) $87 (48–244)
$10 per dose $147 (90–556) $154 (99–487)
Data are median (range) across the models’ medians. ICER=incremental cost-eﬀ ectiveness ratios. *Proportion of 
additional events averted with four-dose versus three-dose immunisation schedule.
Table 2: Predictions of public health impact and cost-eﬀ ectiveness of RTS,S for the 6–9 month three-dose 
and four-dose immunisation schedules at 15 years of follow-up in regions with a parasite prevalence in 
2–10 year olds of 10–65%
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the extra deaths averted with the four-dose schedule are 
oﬀ set by the extra costs estimated for delivery of the 
fourth dose, and because of our assumption that only 
80% of children who receive the ﬁ rst three doses will 
return for the fourth dose. In a sensitivity analysis, the 
cost per DALY averted over the 15 year time horizon at 
Figure 4: Cost per clinical case or DALY averted as a function of baseline parasite prevalence in 2–10 year olds (PfPR2–10)
Results assume a vaccine price of $2 (A, D), $5 (B, E), or $10 (C, E) per dose. Solid lines represent a three-dose immunisation schedule and dashed lines represent a 
four-dose immunisation schedule. Similar estimates of incremental cost-eﬀ ectiveness ratios were obtained for the three-dose and four-dose schedules because the 
additional public health beneﬁ t of the boosted schedule is oﬀ set by the incremental cost of implementation of the additional dose. Uncertainty estimates 
surrounding the models’ predictions are omitted for readability but overlap. DALY=disability-adjusted life-year. 
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Figure 3: Clinical cases averted in the vaccinated cohort at low (A) and high (B) endemicity after 15 years of routine use of RTS,S in a four-dose immunisation schedule
Bars show median predictions over all four models and error bars show the range of predictions. Uncertainty within each model is not shown (see appendix pp 5–7). 
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most doubled from the baseline estimate when we 
considered a range of factors including lower vaccination 
coverage, lower estimates of vaccine eﬃ  cacy, and higher 
vaccine price, with the greatest impact due to a price 
increase from $5 to $10 (appendix pp 48–50).
Discussion
We predict a positive public health impact of the 
introduction of RTS,S/AS01 in settings with a PfPR2–10 
between 3% and 65% over a 15 year time horizon with 
treatment levels representative of the current status in 
Africa. The absolute impact is substantial, with an 
estimated 116 500 (range 30 900–160 000) cases of 
clinical malaria and 484 (195–838) deaths averted per 
100 000 vaccinated children with a four-dose schedule for a 
PfPR2–10 between 10% and 65%. This ﬁ nding translates to 
roughly one malaria death prevented for every 200 children 
fully vaccinated, which, at a vaccine price per dose of $5, 
equates to $87 (range 43–238) per DALY averted. WHO 
estimates that 528 000 (range 315 000–689 000) malaria 
deaths occurred in Africa in 2013.1 Depending on the area 
of implementation, we estimate that 6–30% of deaths in 
children younger than 5 years could potentially be averted 
by RTS,S, when added to existing coverage of long-lasting 
insecticide-treated nets (68%1,22) and with moderate levels 
of malaria treatment.
There was no statistically signiﬁ cant impact against 
severe disease measured in the trial for the three-dose 
schedule (4·5%, 95% CI –20·6 to 24·5 at 32 months’ 
follow-up in the group aged 5–17 months), although 
there was sustained signiﬁ cant eﬃ  cacy with the four-dose 
schedule (32·2%, 13·7–46·9).3 Moreover, there was no 
statistically signiﬁ cant impact on malaria mortality and 
all-cause mortality, although numbers of deaths were 
small and the trial was not powered to assess this 
outcome.3 By contrast, we predicted a net positive impact 
on severe disease cases and hence deaths averted with 
the three-dose schedule, with an incremental beneﬁ t of 
the fourth dose of 22% extra deaths averted depending 
on the setting. There are several possible reasons for this 
discrepancy. First, severe disease incidence in the trial 
was low, with substantial diﬀ erences between sites in the 
point estimates and wide conﬁ dence intervals. Second, 
inferences about severe disease made by the models are 
based mainly on data from sites with poorer quality of 
care than in the trial and broader case deﬁ nitions.23 
Third, the model projections assume that the fourth dose 
reaches only 80% of the third-dose recipients, and 
consequently only 72% of the eligible population receive 
four doses (compared with near 100% coverage in the 
trial). Finally, these projections are for a 15 year time 
horizon whereas the trial data include a maximum 
of 4 years of follow-up. Partially protective malaria 
interventions reduce an individual’s exposure to malaria 
infection resulting in a delay in the acquisition of natural 
immunity19,20 and a shift of clinical and severe disease to 
older ages.19–21 This shift is predicted to be greatest in 
scenarios with high initial vaccine impact. Much of the 
age-shift eﬀ ect is predicted to happen beyond 3·5–4 years 
and at a PfPR2–10 at the upper end of or higher than the 
PfPR2–10 in the trial, and is therefore not expected to be 
shown in the trial. As such, longer-term follow-up of trial 
participants is needed to fully understand any shifting of 
cases to older age groups, with this shift partly shown in 
the 4 year follow-up of one of the phase 2 trials.24
For regions where PfPR2–10 is more than 10%, RTS,S is 
predicted to be cost-eﬀ ective compared with standard 
norms and thresholds. Broadly similar ICER estimates 
were obtained for the three-dose and four-dose schedules, 
with the additional public health beneﬁ t of the boosting 
schedule oﬀ set by the incremental cost of implementation 
of the additional dose. The higher cost of the four-dose 
versus the three-dose schedule is partly due to our 
assumption (based on the diﬀ erence between DTP3 and 
ﬁ rst-dose measles vaccination coverage in Africa16) that 
only 80% of children who receive the ﬁ rst three doses 
would return for the fourth dose.16 At low prevalence 
(PfPR2–10 3%), when cases typically occur in older children 
and adults, we consistently noted that the vaccine was 
not cost-eﬀ ective. Except for at very low prevalence, our 
estimated ICERs are lower than the national 
gross domestic products per person (median $842 
[IQR 531–1668] across 43 malaria-endemic African 
countries with PfPR2–10>10% in 20142). Furthermore, in 
settings with PfPR2–10 levels of 20% or greater, ICERs at a 
vaccine price of $5 are less than $100 per DALY averted. 
A 2011 review25 summarised average incremental costs 
per DALY averted (2009 prices) for long-lasting 
insecticide-treated nets of $27 (range 8·15–110), 
insecticide residual spraying of $143 (135–150), and 
intermittent preventative treatment of $24 (1·08–44·24). 
Additionally, economic assessment of long-lasting 
insecticide-treated nets from large-scale ﬁ eld studies26,27 
estimated that the cost per DALY averted was between 
$13 and $89. However, there was wide variation in the 
costing methodologies used and economies of scale 
captured by these studies; therefore, these ﬁ gures should 
be interpreted as indicative ranges rather than directly 
corresponding to our estimates. With these caveats, 
RTS,S is somewhat less cost-eﬀ ective than long-lasting 
insecticide-treated nets, which are regarded as one of the 
most cost-eﬀ ective interventions available for malaria 
control; this is an important point for countries to bear in 
mind because use of long-lasting insecticide-treated nets 
has also led to proven reductions in all-cause mortality.27
Despite the diﬀ erences between the models, all 
four groups reached consensus about the expected public 
health impact and cost-eﬀ ectiveness of RTS,S/AS01 
administration to children aged 6–9 months, and their 
consensus predictions help to deﬁ ne priority areas 
by levels of PfPR2–10 for policy recommendation. The 
systematic and harmonised comparison of multiple 
models aided interpretation of diﬀ erences between the 
models, with these diﬀ erences relating mostly to model 
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characteristics that were evident in baseline model 
associations and baseline incidence in absence of 
vaccine. These characteristics include diﬀ erences in 
relations between parasite prevalence and clinical 
incidence; case deﬁ nitions; assumptions about rates of 
immune acquisition, immune decay, mechanisms of 
immunity; and diﬀ erences due to datasets used for 
parameterisation.
Our analysis has some limitations. First, although the 
estimated vaccine eﬃ  cacy and waning proﬁ le was 
similar across the models, these proﬁ les diverged after 
18 months of follow-up. The predicted long-term 
impact of the vaccine will inevitably depend on the 
pattern of these proﬁ les and hence they should be 
updated with extended follow-up data. Second, whereas 
the models reproduce vaccine eﬃ  cacy estimates from 
the trial, the projections of impact on disease and 
mortality are based on previous model-ﬁ tting to 
historical data relating clinical and severe incidence to 
mortality, in the assumption that associations in 
settings with more restricted access to health care are 
similar to those in settings with good access. Unlike the 
trials of insecticide-treated nets,27 which showed 
statistically signiﬁ cant reductions in malaria mortality, 
there was no signiﬁ cant impact on malaria mortality or 
all-cause mortality in the RTS,S trial. This outcome is 
likely to be due to the signiﬁ cantly lower levels of 
overall mortality in trial participants with high access to 
care than in those with low access. Nevertheless, the 
modelled estimates of RTS,S impact on mortality need 
further validation, and future studies done after 
implementation should include monitoring of impact 
on mortality. Third, we assumed that vaccination would 
be implemented at 6–9 months with three or four doses, 
yet actual implementation schedules and coverage 
might diﬀ er (including more than four doses). Over 
this age range, naturally acquired immunity develops 
rapidly and physiological eﬀ ects can also aﬀ ect the 
maturity of the vaccine-induced antibody response.28 
Fourth, only two of the models allowed for possible 
indirect eﬀ ects on transmission, with one model 
predicting indirect eﬀ ects in settings with low malaria 
prevalence. Although the main aim of the vaccine is to 
provide direct protection, assessment of any indirect 
eﬀ ects will be important in the post-licensure phase. 
Finally, we did not include productivity losses to 
households, and costs of immunisation and disease 
management were considered from a health-system 
perspective in our economic analysis. According to 
WHO guidelines,29 the societal perspective is generally 
preferred; however, in practice, this approach is rarely 
taken because not all costs are available. In general, 
addition of costs beyond the health system would 
increase the cost-eﬀ ectiveness of vaccination, making 
our estimates lower. Despite these limitations, our 
results can help inform decisions about where to 
implement RTS,S to have the greatest impact.
WHO coordinated this model comparison process as 
an important contributory factor to the broader 
assessment processes related to this vaccine. These 
models did not incorporate safety aspects, as is standard 
for cost-eﬀ ectiveness and impact models at the 
pre-licensure stage.7 These safety aspects include 
immediate reactogenicity including fever (noted with 
many vaccines), the identiﬁ ed risk of febrile convulsion 
within 7 days of vaccination (also not unique to this 
vaccine), and the potential risk of meningitis (which has 
not been causally related to vaccination), and are outlined 
in the June, 2014, report of the WHO Global Advisory 
Committee on Vaccine Safety.30 The WHO policy 
recommendation processes underway take all these 
elements into account as part of an overall assessment of 
beneﬁ ts and harms, resource use and value for money, 
equity impacts, feasibility, and acceptability.
Contributors
MAP, RV, and ACG conceived the study and designed the model 
comparison. MAP, RV, KG, MTW, JTG, ACG, CAB, EAW, and CS 
designed individual model group analysis. KG provided costing data. 
KG, JTG, and CS provided data. MAP, RV, CAB, CS, KG, MTW, NVdV, 
JTG, and PP-R did the analyses. SF, EAW, TAS, PAE, and ACG 
supported the analyses. MAP, SF, EAW, TAS, FM, MJ, and ACG 
supported interpretation and policy contextualisation. MAP wrote the 
ﬁ rst draft of the manuscript. MAP, ACG, RV, SF, FM, and TAS wrote the 
manuscript. MAP, RV, CAB, CS, KG, SF, MTW, FM, and ACG compiled 
the information in the appendix. All authors discussed the results and 
contributed to revision of the ﬁ nal manuscript.
Declaration of interests
FM is employed by PATH. CS and NVdV are employed by the GSK 
group of companies. All other authors declare no competing interests.
Acknowledgments
Imperial College London and Swiss Tropical and Public Health Institute 
received funding from the PATH Malaria Vaccine Initiative and the 
Bill & Melinda Gates Foundation. Work done by the Institute for Disease 
Modeling was funded by the Global Good Fund of Bellevue, WA, USA.
The London School of Hygiene & Tropical Medicine (SF, MJ) received 
funding from WHO and GAVI, the Vaccine Alliance. Imperial College 
London received additional fellowship (JTG, MTW) and centre (ACG) 
funding from the Medical Research Council (MRC) and the UK 
Department for International Development (DFID) under the MRC/DFID 
concordat agreement. No funding was provided by GlaxoSmithKline 
Biologicals SA to the non-GSK modelling groups or the comparison 
process as a whole. We thank Vasee Moorthy and Raymond Hutubessy 
(WHO, Geneva, Switzerland) for their role in bringing this consortium 
together and initiating the work outlined in this report; members of the 
WHO Joint Technical Expert Group on malaria vaccine modelling 
subgroup for their constructive comments; and Alison Reynolds for her 
support in undertaking this work. Calculations for OpenMalaria were 
done at the Centre for Scientiﬁ c Computing (sciCORE) at the University 
of Basel, Switzerland, and we thank the many volunteers who made their 
computers available via www.malariacontrol.net for the simulations.
References
1 WHO. World malaria report 2013. Geneva: World Health 
Organization, 2014.
2 Bhatt S, Weiss DJ, Cameron E, et al. The eﬀ ect of malaria control on 
Plasmodium falciparum in Africa between 2000 and 2015. Nature 
2015; 526: 207–11.
3 RTSS Clinical Trials Partnership. Eﬃ  cacy and safety of RTS,S/AS01 
malaria vaccine with or without a booster dose in infants and 
children in Africa: ﬁ nal results of a phase 3, individually 
randomised, controlled trial. Lancet 2015; 386: 31–45.
4 Patil AP, Okiro EA, Gething PW, et al. Deﬁ ning the relationship 
between Plasmodium falciparum parasite rate and clinical disease: 
statistical models for disease burden estimation. Malar J 2009; 8: 186.
Articles
www.thelancet.com   Vol 387   January 23, 2016 375
5 Hamel MJ, Oneko M, Williamson J, et al. A marked reduction in 
mortality among participants in a clinical trial that removed barriers 
to care and implemented national case management guidelines. 
63rd Annual meeting of the American Society of Tropical Medicine 
and Hygiene; New Orleans, LA; Nov 2–6, 2014. 631 (abstr).
6 Hutubessy R, Henao AM, Namgyal P, Moorthy V, Hombach J. 
Results from evaluations of models and cost-eﬀ ectiveness tools to 
support introduction decisions for new vaccines need critical 
appraisal. BMC Med 2011; 9: 55.
7 Moorthy VS, Hutubessy R, Newman RD, Hombach J. 
Decision-making on malaria vaccine introduction: the role of 
cost-eﬀ ectiveness analyses. Bull World Health Organ 2012; 90: 864–66.
8 Lee LA, Franzel L, Atwell J, et al. The estimated mortality impact 
of vaccinations forecast to be administered during 2011–2020 in 
73 countries supported by the GAVI Alliance. Vaccine 2013; 
31: B61–72.
9 McCarthy KA, Wenger EA, Huynh GH, Eckhoﬀ  PA. Calibration of 
an intrahost malaria model and parameter ensemble evaluation of a 
pre-erythrocytic vaccine. Malar J 2015; 14: 6.
10 Sauboin C, Van Vlaenderen I, Van Bellinghen LA, Standaert B. 
Cost-eﬀ ectiveness of RTS,S malaria vaccine candidate in children 
estimated using a Markov cohort model and phase 3 trial results. 
3rd International Conference of the African Health Economics and 
Policy Association; Nairobi, Kenya; March 11–13, 2014. 40 (abstr).
11 Griﬃ  n JT, Ferguson NM, Ghani AC. Estimates of the changing 
age-burden of Plasmodium falciparum malaria disease in 
sub-Saharan Africa. Nat Commun 2014; 5: 3136.
12 Smith T, Ross A, Maire N, et al. Ensemble modeling of the likely 
public health impact of a pre-erythrocytic malaria vaccine. 
PLoS Med 2012; 9: 44.
13 Penny MA, Galactionova K, Tarantino M, Tanner M, Smith TA. 
The public health impact of malaria vaccine RTS, S in malaria 
endemic Africa: country-speciﬁ c predictions using 18 month 
follow-up phase III data and simulation models. BMC Med 2015; 
13: 170.
14 White MT, Verity R, Griﬃ  n JT, et al. Immunogenicity of the 
RTS,S/AS01 malaria vaccine over time and implications for 
duration of vaccine eﬃ  cacy: analysis of data from a phase 3 
randomised controlled trial. Lancet Infect Dis 2015; published online 
Sept 2. http://dx.doi.org:10.1016/S1473-3099(15)00239-X.
15 INDEPTH Network. Model life tables for sub-Saharan Africa. 
Aldershot: Ashgate Publishing; 2004.
16 WHO. WHO–UNICEF estimates of DTP3 coverage. 2013. 
http://apps.who.int/immunization_monitoring/globalsummary/
timeseries/tswucoveragedtp3.html (accessed Dec 1, 2014).
17 World Health Organization. Global technical strategy for malaria 
2016–2030. Geneva: World Health Organization, 2015.
18 The RTSS Clinical Trials Partnership. Eﬃ  cacy and safety of the 
RTS,S/AS01 malaria vaccine during 18 months after vaccination: 
a phase 3 randomized, controlled trial in children and young 
infants at 11 African Sites. PLoS Med 2014; 11: e1001685.
19 Greenwood BM, David PH, Otoo-Forbes LN, et al. Mortality and 
morbidity from malaria after stopping malaria chemoprophylaxis. 
Trans R Soc Trop Med Hyg 1995; 89: 629–33.
20 Aponte JJ, Menendez C, Schellenberg D, et al. Age interactions in 
the development of naturally acquired immunity to 
Plasmodium falciparum and its clinical presentation. PLoS Med 
2007; 4: e242.
21 Gosling RD, Ghani AC, Deen JL, von Seidlein L, Greenwood BM, 
Chandramohan D. Can changes in malaria transmission intensity 
explain prolonged protection and contribute to high protective 
eﬃ  cacy of intermittent preventive treatment for malaria in infants? 
Malar J 2008; 7: 54.
22 WHO, UN Children’s Fund. Achieving the malaria MDG target: 
reversing the incidence of malaria 2000–2015. Geneva: World 
Health Organization, 2015.
23 Marsh K, Snow R. Malaria transmission and morbidity. 
Parassitologia 1999; 41: 241–46.
24 Olotu A, Fegan G, Wambua J, et al. Four-year eﬃ  cacy of 
RTS,S/AS01E and its interaction with malaria exposure. 
N Engl J Med 2013; 368: 1111–20.
25 White MT, Conteh L, Cibulskis R, Ghani AC. Costs and 
cost-eﬀ ectiveness of malaria control interventions—a systematic 
review. Malar J 2011; 10: 337.
26 Yukich JO, Lengeler C, Tediosi F, et al. Costs and consequences of 
large-scale vector control for malaria. Malar J 2008; 7: 258.
27 Lengeler C. Insecticide-treated bed nets and curtains for preventing 
malaria. Cochrane Database Syst Rev 2004; 2: CD000363.
28 White MT, Griﬃ  n JT, Akpogheneta O, et al. Dynamics of the 
antibody response to Plasmodium falciparum infection in African 
children. J Infect Dis 2014; 210: 1115–22.
29 WHO. WHO guide for standardization of economic evaluations of 
immunization programmes. Geneva: World Health 
Organization, 2008.
30 WHO. Global Advisory Committee on Vaccine Safety, 
11–12 June 2014. Wkly Epidemiol Rec 2014; 89: 325–35.
